In some embodiments, the otic formulation or composition comprises about 0.04% by weight of the therapeutic agent, or pharmaceutically acceptable prodrug or salt thereof
It is derived from the -melanocyte-stimulating hormone (-MSH) molecule, which is involved in orchestrating the bodys own internal anti-inflammatory mechanism
In some embodiments, the formulations described herein have a pH and/or practical osmolarity as described herein, and have a concentration of active pharmaceutical ingredient from about 0.0001% to about 60%, from about 0.001% to about 40%, from about 0.01% to about 20%, from about 0.01% to about 10%, from about 0.01% to about 7.5%, from about 0.01% to about 6%, from about 0.01 to about 5%, from about 0.1 to about 10%, or from about 0.1 to about 6% of the active ingredient by weight of the formulation
4 Pharmacokinetics of Ipamorelin (PubMed)Onset and short ~2 hour half-life of Ipamorelin after subcutaneous administration
Ayoub E, Lehotzky D, Li L, Muftuoglu M, Nishida Y, Mohanty V, Leighton JS, Patsilevas T, Basyal M, Bedoy A, Haftarah T, Takahashi K, Chen K, Navin N, Issa GC, Getz G, Andreeff M
Usually, doses are between 1,000 to 2,500 mcg per shot